Navigation Links
New study refutes existence and clinical potential of very small embryonic-like stem cells
Date:7/28/2013

Scientists have reported that very small embryonic-like stem cells (VSELs), which can be isolated from blood or bone marrow rather than embryos, could represent an alternative to mouse and human embryonic stem cells for research and medicine. But their very existence is hotly debated, and a study appearing online on July 24th in the ISSCR's journal Stem Cell Reports, published by Cell Press, provides strong evidence against the existence of VSELs capable of turning into different cell types. The findings call into question current plans to launch a clinical trial aimed at testing whether VSELs can be used for regenerative medicine in humans.

"To know when a stem cell discovery is true, it must meet several criteria," says senior study author Irving Weissman of Stanford University School of Medicine. "First, the work must be published in a peer-reviewed journal; second, other labs in the field should be able to repeat the findings; third, the phenomenon should be so robust that other experimental methods must reveal it; and fourth, in the stem cell field, the regeneration that occurs must be rapid, robust, and lifelong. In our study, we did not find evidence supporting the second, third, and fourth requirements."

In 2006, a group of researchers first reported the presence of VSELs in mice. Subsequent studies have provided evidence that these cells also exist in human blood and bone marrow and could turn into specialized cells such as lung cells, a finding which may be useful for replacing damaged tissue. But other labs have failed to replicate these findings. Nonetheless, a biopharmaceutical company called Neostem, which acquired the exclusive license to VSEL technology, plans to apply for Food and Drug Administration approval to carry out a first-in-man trial to test whether VSELs can regenerate bone.

In light of these conflicting results, Weissman and his team made the most rigorous effort yet to replicate the original VSEL findings. Although they used a variety of protocols, they failed to find VSELs derived from mouse bone marrow that could turn into specialized blood cells. Instead, the "VSELs" appeared to be artifacts such as cell debris and fragments from dying cells. "Our findings clearly refute the basis in mouse studies that VSELs have the potentials claimed, and therefore call into question claims that these cells have potential for clinical application in humans," Weissman says.

Another article that will be published on the same day in the journal Cell Stem Cell reviews the controversy surrounding VSELs and includes wide-ranging commentary from experts in the field.


'/>"/>

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related biology technology :

1. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
2. NEBA Health Releases Key Study Results for the first FDA approved brain wave test to help clinicians assess ADHD in children and adolescents
3. Novel study using new technologies outlines importance of California condor social groups
4. 2013 NASA Advanced Technology Phase I Concepts Selected For Study
5. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
6. Study puts troubling traits of H7N9 avian flu virus on display
7. DOs and DON’Ts of Study Start-Up: Best Practices to Improve Efficiency and Meet/Exceed Timelines, New Life Science Webinar Hosted by Xtalks
8. Study Scavenger and JALR.org Announce Alliance Utilizing Smart Phone Capabilities to Bring Clinical Trials to Motivated Subjects
9. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
10. New Study Reveals that PEEK Polymer Spinal Cage Is Superior to Titanium in Surgical Treatment of Multilevel Cervical Spondylotic Myelopathy
11. Americord Applauds Study on Stem Cell Therapy for Congenital Heart Defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in an ... on RFD-TV. , With global population estimates nearing ten billion people by 2050, ... a growing nation. At the same time, many of our valuable resources are becoming ...
Breaking Biology Technology:
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):